ATRA
Atara Biotherapeutics, Inc.
Price Chart
Latest Quote
$9.62
-0.34 (-3.41%)
Current Price
| Previous Close | $9.96 |
| Open | $9.92 |
| Day High | $9.98 |
| Day Low | $9.21 |
| Volume | 126,095 |
Stock Information
| Shares Outstanding | 9.01M |
| Total Debt | $10.09M |
| Cash Equivalents | $8.36M |
| Revenue | $23.14M |
| Net Income | $-9.47M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $86.68M |
| EPS (TTM) | $-1.22 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $88.41M |
| Sales | $23.14M |
| Income | $-9.47M |
| Book/sh | $-4.38 |
| Cash/sh | $0.93 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 1.48 |
| Current Ratio | 2.16 |
Returns & Margins
| ROA | -3.83% |
| Gross Margin | 70.11% |
| Operating Margin | -652.91% |
| Profit Margin | -40.91% |
Ownership
| Insider Ownership | 16.66% |
| Institutional Ownership | 52.46% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 5.88 |
| P/S | 3.75 |
| P/B | -2.19 |
Analyst Data
| Recommendation | none |
| Target Price | $13.67 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 44.27 |
| ATR | nan |
| Shares Float | 4.72M |
| Short Float | 7.66% |
| Short Ratio | 0.12 |
| Volatility | 0.11 |
| Rel Volume | 1.18 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $nan | 126,095 |
| 2026-06-15 | $9.96 | 80,700 |
| 2026-06-12 | $10.41 | 95,600 |
| 2026-06-11 | $10.46 | 42,800 |
| 2026-06-10 | $9.86 | 56,400 |
| 2026-06-09 | $9.77 | 65,900 |
| 2026-06-08 | $9.58 | 113,200 |
| 2026-06-05 | $9.92 | 69,000 |
| 2026-06-04 | $10.27 | 94,400 |
| 2026-06-03 | $9.63 | 104,200 |
| 2026-06-02 | $9.90 | 62,700 |
| 2026-06-01 | $10.28 | 90,100 |
| 2026-05-29 | $10.51 | 96,400 |
| 2026-05-28 | $11.26 | 146,700 |
| 2026-05-27 | $10.54 | 168,900 |
| 2026-05-26 | $9.61 | 182,300 |
| 2026-05-22 | $9.80 | 122,600 |
| 2026-05-21 | $9.34 | 52,600 |
| 2026-05-20 | $9.45 | 80,400 |
| 2026-05-19 | $9.41 | 286,600 |
| 2026-05-18 | $9.15 | 382,600 |
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
đ° Latest News
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
Zacks âĸ 2026-05-21T14:37:00Z
FDA Resubmission Path for Tab-cel Keeps Ataraâs (ATRA) Regulatory Timeline Alive
InvestorsHub âĸ 2026-05-07T15:03:50Z
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
Insider Monkey âĸ 2026-04-03T00:02:34Z
Atara Biotherapeutics: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-16T20:35:03ZPierre Fabre seeks to revive US approval chances for spurned cell therapy
BioPharma Dive âĸ 2026-03-03T11:52:51Z
Top Midday Decliners
MT Newswires âĸ 2026-01-13T19:14:40ZAbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
BioPharma Dive âĸ 2026-01-12T11:24:00Z
Atara Biotherapeutics: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T14:11:10ZWave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-10T13:45:02Z
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Zacks âĸ 2025-11-07T11:45:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $21,212,000 | $21,009,000 | $8,886,000 | $0 |
| Cost Of Revenue | $21,212,000 | $21,009,000 | $8,886,000 | $0 |
| Total Revenue | $120,772,000 | $128,940,000 | $8,573,000 | $63,573,000 |
| Operating Revenue | $120,772,000 | $128,940,000 | $8,573,000 | $63,573,000 |
| Expenses | ||||
| Interest Expense | $3,792,000 | $4,615,000 | $5,285,000 | $373,000 |
| Total Expenses | $84,910,000 | $212,378,000 | $284,579,000 | $344,086,000 |
| Other Income Expense | $-34,000 | $528,000 | $-246,000 | $49,537,000 |
| Other Non Operating Income Expenses | $-34,000 | $528,000 | $-246,000 | $-700,000 |
| Net Non Operating Interest Income Expense | $-3,109,000 | $-2,505,000 | $141,000 | $2,686,000 |
| Interest Expense Non Operating | $3,792,000 | $4,615,000 | $5,285,000 | $373,000 |
| Operating Expense | $63,698,000 | $191,369,000 | $275,693,000 | $344,086,000 |
| General And Administrative Expense | $26,253,000 | $39,886,000 | $50,908,000 | $71,553,000 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $32,688,000 | $-85,403,000 | $-276,126,000 | $-228,302,000 |
| Net Interest Income | $-3,109,000 | $-2,505,000 | $141,000 | $2,686,000 |
| Interest Income | $683,000 | $2,110,000 | $5,426,000 | $3,059,000 |
| Normalized Income | $32,688,000 | $-85,403,000 | $-276,126,000 | $-278,539,000 |
| Net Income From Continuing And Discontinued Operation | $32,688,000 | $-85,403,000 | $-276,126,000 | $-228,302,000 |
| Total Operating Income As Reported | $35,862,000 | $-83,438,000 | $-276,006,000 | $-280,513,000 |
| Net Income Common Stockholders | $32,688,000 | $-85,403,000 | $-276,126,000 | $-228,302,000 |
| Net Income | $32,688,000 | $-85,403,000 | $-276,126,000 | $-228,302,000 |
| Net Income Including Noncontrolling Interests | $32,688,000 | $-85,403,000 | $-276,126,000 | $-228,302,000 |
| Net Income Continuous Operations | $32,688,000 | $-85,403,000 | $-276,126,000 | $-228,302,000 |
| Pretax Income | $32,719,000 | $-85,415,000 | $-276,111,000 | $-228,290,000 |
| Interest Income Non Operating | $683,000 | $2,110,000 | $5,426,000 | $3,059,000 |
| Operating Income | $35,862,000 | $-83,438,000 | $-276,006,000 | $-280,513,000 |
| Gross Profit | $99,560,000 | $107,931,000 | $-313,000 | $63,573,000 |
| Special Income Charges | - | - | $0 | $50,237,000 |
| Per Share | ||||
| Diluted EPS | $2.57 | $-11.41 | $-65.19 | $-56.00 |
| Basic EPS | $2.61 | $-11.41 | $-65.19 | $-56.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $38,627,000 | $-75,749,000 | $-265,997,000 | $-272,501,000 |
| Reconciled Depreciation | $2,116,000 | $5,051,000 | $4,829,000 | $5,653,000 |
| EBITDA (Bullshit earnings) | $38,627,000 | $-75,749,000 | $-265,997,000 | $-222,264,000 |
| EBIT | $36,511,000 | $-80,800,000 | $-270,826,000 | $-227,917,000 |
| Diluted Average Shares | $12,718,000 | $7,488,000 | $4,236,000 | $4,079,600 |
| Basic Average Shares | $12,544,000 | $7,488,000 | $4,236,000 | $4,079,600 |
| Diluted NI Availto Com Stockholders | $32,688,000 | $-85,403,000 | $-276,126,000 | $-228,302,000 |
| Tax Provision | $31,000 | $-12,000 | $15,000 | $12,000 |
| Research And Development | $37,445,000 | $151,483,000 | $224,785,000 | $272,533,000 |
| Selling General And Administration | $26,253,000 | $39,886,000 | $50,908,000 | $71,553,000 |
| Other Gand A | $26,253,000 | $39,886,000 | $50,908,000 | $71,553,000 |
| Total Unusual Items | - | - | $0 | $50,237,000 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $50,237,000 |
| Gain On Sale Of Ppe | - | - | $0 | $50,237,000 |
Fetched: 2026-06-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-38,502,000 | $-97,283,000 | $-99,231,000 | $126,640,000 |
| Total Assets | $20,235,000 | $109,098,000 | $165,504,000 | $376,420,000 |
| Total Non Current Assets | $8,023,000 | $44,204,000 | $63,635,000 | $81,340,000 |
| Other Non Current Assets | $886,000 | $3,103,000 | $4,844,000 | $7,018,000 |
| Current Assets | $12,212,000 | $64,894,000 | $101,869,000 | $295,080,000 |
| Other Current Assets | $2,477,000 | $10,115,000 | $6,184,000 | $10,308,000 |
| Restricted Cash | $0 | $146,000 | $146,000 | $146,000 |
| Inventory | $0 | $10,655,000 | $9,706,000 | $1,586,000 |
| Receivables | $1,253,000 | $1,482,000 | $34,108,000 | $40,221,000 |
| Accounts Receivable | $1,253,000 | $1,482,000 | $34,108,000 | $40,221,000 |
| Cash Cash Equivalents And Short Term Investments | $8,482,000 | $42,496,000 | $51,725,000 | $242,819,000 |
| Cash And Cash Equivalents | $8,482,000 | $25,030,000 | $25,841,000 | $92,942,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $10,375,000 | $43,831,000 | $57,872,000 | $71,704,000 |
| Long Term Debt And Capital Lease Obligation | $9,347,000 | $29,914,000 | $45,693,000 | $58,064,000 |
| Current Debt And Capital Lease Obligation | $1,028,000 | $13,917,000 | $12,179,000 | $13,640,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $58,737,000 | $206,381,000 | $264,735,000 | $249,780,000 |
| Total Non Current Liabilities Net Minority Interest | $43,815,000 | $71,807,000 | $122,509,000 | $170,864,000 |
| Other Non Current Liabilities | $34,468,000 | $41,893,000 | $39,254,000 | $35,800,000 |
| Current Liabilities | $14,922,000 | $134,574,000 | $142,226,000 | $78,916,000 |
| Other Current Liabilities | $9,750,000 | $382,000 | - | - |
| Current Deferred Liabilities | $716,000 | $95,092,000 | $77,833,000 | $8,000,000 |
| Payables And Accrued Expenses | $2,157,000 | $18,594,000 | $40,695,000 | $39,617,000 |
| Payables | $127,000 | $4,367,000 | $3,684,000 | $6,871,000 |
| Accounts Payable | $127,000 | $4,367,000 | $3,684,000 | $6,871,000 |
| Non Current Deferred Liabilities | - | $0 | $37,562,000 | $77,000,000 |
| Equity | ||||
| Common Stock Equity | $-38,502,000 | $-97,283,000 | $-99,231,000 | $126,640,000 |
| Total Equity Gross Minority Interest | $-38,502,000 | $-97,283,000 | $-99,231,000 | $126,640,000 |
| Stockholders Equity | $-38,502,000 | $-97,283,000 | $-99,231,000 | $126,640,000 |
| Gains Losses Not Affecting Retained Earnings | $1,000 | $8,000 | $-204,000 | $-2,067,000 |
| Other Equity Adjustments | $1,000 | $8,000 | $-204,000 | $-2,067,000 |
| Retained Earnings | $-2,021,865,000 | $-2,054,553,000 | $-1,969,150,000 | $-1,693,024,000 |
| Other | ||||
| Ordinary Shares Number | $7,324,000 | $5,858,909 | $4,257,880 | $3,837,080 |
| Share Issued | $7,324,000 | $5,858,909 | $4,257,880 | $3,837,080 |
| Tangible Book Value | $-38,502,000 | $-97,283,000 | $-99,231,000 | $126,640,000 |
| Invested Capital | $-38,502,000 | $-97,283,000 | $-99,231,000 | $126,640,000 |
| Working Capital | $-2,710,000 | $-69,680,000 | $-40,357,000 | $216,164,000 |
| Capital Lease Obligations | $10,375,000 | $43,831,000 | $57,872,000 | $71,704,000 |
| Total Capitalization | $-38,502,000 | $-97,283,000 | $-99,231,000 | $126,640,000 |
| Additional Paid In Capital | $1,983,361,000 | $1,957,261,000 | $1,870,123,000 | $1,821,721,000 |
| Capital Stock | $1,000 | $1,000 | $0 | $10,000 |
| Common Stock | $1,000 | $1,000 | $0 | $10,000 |
| Long Term Capital Lease Obligation | $9,347,000 | $29,914,000 | $45,693,000 | $58,064,000 |
| Current Deferred Revenue | $716,000 | $95,092,000 | $77,833,000 | $8,000,000 |
| Current Capital Lease Obligation | $1,028,000 | $13,917,000 | $12,179,000 | $13,640,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,271,000 | $6,589,000 | $11,519,000 | $17,659,000 |
| Current Accrued Expenses | $2,030,000 | $14,227,000 | $37,011,000 | $32,746,000 |
| Net PPE | $7,137,000 | $41,101,000 | $58,791,000 | $74,322,000 |
| Accumulated Depreciation | $-213,000 | $-17,307,000 | $-15,869,000 | $-12,422,000 |
| Gross PPE | $7,350,000 | $58,408,000 | $74,660,000 | $86,744,000 |
| Leases | $67,000 | $930,000 | $904,000 | $875,000 |
| Other Properties | $7,064,000 | $54,253,000 | $70,475,000 | $82,819,000 |
| Machinery Furniture Equipment | $219,000 | $3,225,000 | $3,123,000 | $3,018,000 |
| Properties | $0 | $0 | $0 | $0 |
| Work In Process | $0 | $9,691,000 | $7,371,000 | $372,000 |
| Raw Materials | $0 | $964,000 | $2,335,000 | $1,214,000 |
| Other Short Term Investments | $0 | $17,466,000 | $25,884,000 | $149,877,000 |
| Non Current Deferred Revenue | - | $0 | $37,562,000 | $77,000,000 |
| Construction In Progress | - | $0 | $158,000 | $32,000 |
| Treasury Shares Number | - | - | $0 | - |
| Long Term Provisions | - | - | - | $30,236,000 |
Fetched: 2026-06-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-50,940,000 | $-68,963,000 | $-194,200,000 | $-274,623,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-50,940,000 | $-68,717,000 | $-192,977,000 | $-270,430,000 |
| Cash Flow From Continuing Operating Activities | $-50,940,000 | $-68,717,000 | $-192,977,000 | $-270,430,000 |
| Operating Gains Losses | - | - | - | $-50,237,000 |
| Investing Activities | ||||
| Investing Cash Flow | $18,148,000 | $8,624,000 | $123,866,000 | $202,956,000 |
| Cash Flow From Continuing Investing Activities | $18,148,000 | $8,624,000 | $123,866,000 | $202,956,000 |
| Capital Expenditure | - | $-246,000 | $-1,223,000 | $-4,193,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $16,314,000 | $59,951,000 | $2,136,000 | $21,891,000 |
| Financing Cash Flow | $16,098,000 | $59,282,000 | $2,010,000 | $53,084,000 |
| Cash Flow From Continuing Financing Activities | $16,098,000 | $59,282,000 | $2,010,000 | $53,084,000 |
| Net Other Financing Charges | $-1,000 | $-7,000 | $-107,000 | $29,790,000 |
| Net Common Stock Issuance | $16,314,000 | $59,951,000 | $2,136,000 | $21,891,000 |
| Common Stock Issuance | $16,314,000 | $59,951,000 | $2,136,000 | $21,891,000 |
| Other | ||||
| Repayment Of Debt | $-250,000 | $-892,000 | $-947,000 | $-518,000 |
| Interest Paid Supplemental Data | $286,000 | $685,000 | $447,000 | $335,000 |
| Income Tax Paid Supplemental Data | $190,000 | $24,000 | $2,000 | $19,000 |
| End Cash Position | $8,482,000 | $25,176,000 | $25,987,000 | $93,088,000 |
| Beginning Cash Position | $25,176,000 | $25,987,000 | $93,088,000 | $107,478,000 |
| Changes In Cash | $-16,694,000 | $-811,000 | $-67,101,000 | $-14,390,000 |
| Proceeds From Stock Option Exercised | $35,000 | $230,000 | $928,000 | $1,921,000 |
| Net Issuance Payments Of Debt | $-250,000 | $-892,000 | $-947,000 | $-518,000 |
| Net Long Term Debt Issuance | $-250,000 | $-892,000 | $-947,000 | $-518,000 |
| Long Term Debt Payments | $-250,000 | $-892,000 | $-947,000 | $-518,000 |
| Net Investment Purchase And Sale | $17,200,000 | $8,870,000 | $125,064,000 | $112,384,000 |
| Sale Of Investment | $25,085,000 | $28,535,000 | $208,712,000 | $292,973,000 |
| Purchase Of Investment | $-7,885,000 | $-19,665,000 | $-83,648,000 | $-180,589,000 |
| Net PPE Purchase And Sale | $948,000 | $-246,000 | $-1,198,000 | $90,572,000 |
| Sale Of PPE | $948,000 | $0 | $25,000 | $94,765,000 |
| Purchase Of PPE | $0 | $-246,000 | $-1,223,000 | $-4,193,000 |
| Change In Working Capital | $-104,735,000 | $-30,959,000 | $15,341,000 | $-61,468,000 |
| Change In Other Working Capital | $-94,376,000 | $-20,303,000 | $30,395,000 | $-11,468,000 |
| Change In Other Current Liabilities | $-9,968,000 | $-24,017,000 | $-1,430,000 | $-5,588,000 |
| Change In Other Current Assets | $6,185,000 | $-1,208,000 | $1,316,000 | $1,570,000 |
| Change In Payables And Accrued Expense | $-17,460,000 | $-13,623,000 | $-12,933,000 | $-5,161,000 |
| Change In Accrued Expense | $-13,220,000 | $-14,310,000 | $-9,803,000 | $4,050,000 |
| Change In Payable | $-4,240,000 | $687,000 | $-3,130,000 | $-9,211,000 |
| Change In Account Payable | $-4,240,000 | $687,000 | $-3,130,000 | $-9,211,000 |
| Change In Inventory | $10,655,000 | $-4,434,000 | $-8,120,000 | $-1,586,000 |
| Change In Receivables | $229,000 | $32,626,000 | $6,113,000 | $-39,235,000 |
| Changes In Account Receivables | $229,000 | $32,626,000 | $6,113,000 | $-39,235,000 |
| Other Non Cash Items | $4,850,000 | $15,833,000 | $16,801,000 | $9,062,000 |
| Stock Based Compensation | $9,752,000 | $27,001,000 | $45,386,000 | $53,838,000 |
| Asset Impairment Charge | $4,130,000 | $0 | - | - |
| Amortization Of Securities | $259,000 | $-240,000 | $792,000 | $1,024,000 |
| Depreciation Amortization Depletion | $2,116,000 | $5,051,000 | $4,829,000 | $5,653,000 |
| Depreciation And Amortization | $2,116,000 | $5,051,000 | $4,829,000 | $5,653,000 |
| Net Income From Continuing Operations | $32,688,000 | $-85,403,000 | $-276,126,000 | $-228,302,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $-50,237,000 |
| Change In Prepaid Assets | - | - | - | - |
Fetched: 2026-06-13